Orbis Investment Management (US)’s AbbVie ABBV Stock Holding History

Orbis Investment Management (US)’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$12.9M	Sell	140,412 -4,190	-3%	-$368K	12.98%	1
2018 Q3	$13.7M	Buy	144,602 +3,160	+2%	+$300K	9.89%	2
2018 Q2	$13.1M	Buy	141,442 +2,670	+2%	+$261K	9.92%	2
2018 Q1	$13.1M	Sell	138,772 -178	-0.1%	-$19.6K	9.15%	3
2017 Q4	$13.4M	Sell	138,950 -26,848	-16%	-$2.53M	9.12%	2
2017 Q3	$14.7M	Buy	165,798 +18,768	+13%	+$1.43M	9.17%	2
2017 Q2	$10.7M	Buy	147,030 +39,827	+37%	+$2.68M	7.04%	4
2017 Q1	$6.99M	Buy	107,203 +100	+0.1%	+$6.29K	4.87%	8
2016 Q4	$6.71M	Buy	107,103 +19,048	+22%	+$1.16M	4.82%	10
2016 Q3	$5.55M	Sell	88,055 -7,312	-8%	-$473K	3.95%	10
2016 Q2	$5.9M	Sell	95,367 -10,408	-10%	-$634K	4.96%	7
2016 Q1	$6.04M	Buy	105,775 +6,282	+6%	+$350K	5.21%	7
2015 Q4	$5.89M	Buy	99,493 +42,981	+76%	+$2.48M	5.07%	6
2015 Q3	$3.08M	Sell	56,512 -10,430	-16%	-$679K	2.79%	18
2015 Q2	$4.5M	Buy	66,942 +64,261	+2,397%	+$4.2M	3.63%	13
2015 Q1	$157K	Buy	+2,681	New	+$162K	0.13%	25

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Orbis Investment Management (US)'s ABBV Position: Q4 2018 in Review

Orbis Investment Management (US) reduced its AbbVie (ABBV) stake by 2.9% in Q4 2018, selling an estimated $368K and leaving 140,412 shares worth $12.9M. The position accounts for 12.98% of the portfolio, ranked #1.

Orbis Investment Management (US) first reported a position in ABBV in Q1 2015 and has held it in 16 quarters since. The position peaked at $14.7M in Q3 2017. 2,063 funds tracked by Wall St. Rank hold ABBV as of Q4 2018.

Orbis Investment Management (US) held 140,412 shares of AbbVie worth $12.9M as of Q4 2018.
Orbis Investment Management (US) sold 4,190 AbbVie shares in Q4 2018, an estimated $368K.
AbbVie made up 12.98% of Orbis Investment Management (US)'s portfolio in Q4 2018, its #1 holding.
Orbis Investment Management (US) first reported a position in AbbVie in Q1 2015 and has held it in 16 quarters since.
Orbis Investment Management (US)'s AbbVie position peaked at $14.7M in Q3 2017.
2,063 funds tracked by Wall St. Rank held AbbVie as of Q4 2018.

Based on Orbis Investment Management (US)'s 13F filing for Q4 2018, filed 14 Feb 2019.